JP2017505755A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505755A5
JP2017505755A5 JP2016536543A JP2016536543A JP2017505755A5 JP 2017505755 A5 JP2017505755 A5 JP 2017505755A5 JP 2016536543 A JP2016536543 A JP 2016536543A JP 2016536543 A JP2016536543 A JP 2016536543A JP 2017505755 A5 JP2017505755 A5 JP 2017505755A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016536543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505755A (ja
JP6609556B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2014/051058 external-priority patent/WO2015083167A1/en
Publication of JP2017505755A publication Critical patent/JP2017505755A/ja
Publication of JP2017505755A5 publication Critical patent/JP2017505755A5/ja
Application granted granted Critical
Publication of JP6609556B2 publication Critical patent/JP6609556B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016536543A 2013-12-05 2014-12-04 転移がんの治療および予防のための医薬組成物および方法 Active JP6609556B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912156P 2013-12-05 2013-12-05
US61/912,156 2013-12-05
PCT/IL2014/051058 WO2015083167A1 (en) 2013-12-05 2014-12-04 Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer

Publications (3)

Publication Number Publication Date
JP2017505755A JP2017505755A (ja) 2017-02-23
JP2017505755A5 true JP2017505755A5 (https=) 2017-12-14
JP6609556B2 JP6609556B2 (ja) 2019-11-20

Family

ID=52292983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536543A Active JP6609556B2 (ja) 2013-12-05 2014-12-04 転移がんの治療および予防のための医薬組成物および方法

Country Status (11)

Country Link
US (1) US9878015B2 (https=)
EP (1) EP3076988B1 (https=)
JP (1) JP6609556B2 (https=)
KR (1) KR102384795B1 (https=)
CN (1) CN105939724B (https=)
AU (1) AU2014358671B2 (https=)
CA (1) CA2931023C (https=)
DK (1) DK3076988T3 (https=)
ES (1) ES2742856T3 (https=)
IL (1) IL245998B (https=)
WO (1) WO2015083167A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3411711B1 (en) 2016-02-04 2022-08-03 Immune System Key Ltd. Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer
KR20250004754A (ko) * 2022-04-11 2025-01-08 이뮨 시스템 키 엘티디. 증식성 질환의 치료를 위한 bcl2 억제제 및 펩티드 병용 요법
JP7843546B2 (ja) * 2022-05-27 2026-04-10 ジンキュア・コーポレイション 新規なペプチド及びその用途
CN121443625A (zh) * 2023-05-03 2026-01-30 免疫系统密钥有限公司 环状d-肽、其衍生物、组合物及用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2507094T3 (es) * 2004-10-25 2014-10-14 Immune System Key Ltd. Proteína específica del timo
WO2007091240A2 (en) 2006-02-06 2007-08-16 Immune System Key Ltd. Treatment of immunological diseases
WO2007122622A1 (en) * 2006-04-24 2007-11-01 Immune System Key Ltd. Method of treatment of a disease
US20100204097A1 (en) 2006-12-18 2010-08-12 Immune System Key Ltd. Therapeutic methods using a thymus peptide

Similar Documents

Publication Publication Date Title
Bhatt et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status
JP2015505843A5 (https=)
JP2016538344A5 (https=)
RU2017126601A (ru) Способы и композиции для лечения злокачественных опухолей, ассоциированных с мутацией kras
JP2016535009A5 (https=)
TR201906470T4 (tr) İmmünomodülatörler.
JP2016506413A5 (https=)
JP2009538932A5 (https=)
JP2017505755A5 (https=)
WO2008063769A3 (en) Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
JP2016531927A5 (https=)
JP2014533247A5 (https=)
NZ726365A (en) Combinations for treating cancers
JP2016520057A5 (https=)
JP2016519069A5 (https=)
Panahizadeh et al. Cytotoxicity of curcumin against CD44±prostate cancer cells: Roles of miR-383 and miR-708
JP2014510699A5 (https=)
MX2012011668A (es) Peptidos cdca5 y vacunas que incluyen los mismos.
Bowling et al. Emerging developments in ETS-positive prostate cancer therapy
Zhang et al. MAGED4 expression in glioma and upregulation in glioma cell lines with 5-aza-2'-deoxycytidine treatment
RU2018107330A (ru) Индуктор иммунитета
Ooi et al. RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update
EP4461371A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
Kim et al. PIK3CA mutations in hepatocellular carcinoma in Korea
Khorrami et al. The interplay between autophagy and immunogenic cell death: nanomaterial-based strategies for cancer immunotherapy